Glenmark Pharma

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

The likelihood of a short-covering move along with addition of fresh position exists only if Nifty breaches 11,200

According to industry insiders, many more brands are lined up for launch, including one from Cipla

The product comes Pune-based Brinton Pharma; Glenmark's FabiFlu is priced at Rs 73 a tablet

Firm claims trial results showed 28.6% faster viral clearance in overall population, says drug well tolerated with no major side effects

The company further claimed that since favipiravir was an oral therapy, patients could be treated on an out-patient basis without incurring additional hospitalisation expenses

Here are the top headlines of the day

Glenmark also denies making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate Covid-19 patients

NCP legislator Amol Kolhe's letter to Health Minister Harsh Vardhan triggers the DCGI to seek details from the Mumbai-based drugmaker

With the past two day's decline, the share price of Glenmark Pharma has corrected 25 per cent from its 52-week high of Rs 573 touched on June 22, 2020.

All that happened in the markets today

The SGX Nifty was up around 60 points at 7:30 AM, and was indicating an open above 10,300 levels for the Nifty today

Limited revenue visibility is restricting analysts to upgrade earnings even as they have upped the PE multiple for the stock

The company launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.

India is working out ways to grant approval for Favipiravir expeditiously

Long build-up was seen in the Glenmark Futures yesterday

Glenmark is the first pharma company in India to be given an approval by the regulator to start the trial on COVID-19 patients

The stock price of HUL and GSK Consumer rallied 5.08% and 5.72% each on Tuesday

Glenmark will manufacture VWash for HUL over the next one year after which the production arrangement would be reviewed

Consolidated revenue of the company stood at Rs 2,735.56 crore for the quarter under consideration as against Rs 2,555.04 crore for the corresponding period a year ago.